[go: up one dir, main page]

ATE86479T1 - Pharmazeutische matrix mit verzoegerter freisetzung und verfahren. - Google Patents

Pharmazeutische matrix mit verzoegerter freisetzung und verfahren.

Info

Publication number
ATE86479T1
ATE86479T1 AT88904333T AT88904333T ATE86479T1 AT E86479 T1 ATE86479 T1 AT E86479T1 AT 88904333 T AT88904333 T AT 88904333T AT 88904333 T AT88904333 T AT 88904333T AT E86479 T1 ATE86479 T1 AT E86479T1
Authority
AT
Austria
Prior art keywords
ibuprofen
granulation
delayed release
release matrix
erosion
Prior art date
Application number
AT88904333T
Other languages
English (en)
Inventor
Galen Wesley Radebaugh
Thomas Nicholas Julian
Robert Glinecke
Original Assignee
Mcneilab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneilab Inc filed Critical Mcneilab Inc
Application granted granted Critical
Publication of ATE86479T1 publication Critical patent/ATE86479T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT88904333T 1987-04-22 1988-04-22 Pharmazeutische matrix mit verzoegerter freisetzung und verfahren. ATE86479T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/041,164 US4806359A (en) 1987-04-22 1987-04-22 Iburprofen sustained release matrix and process
EP88904333A EP0312581B1 (de) 1987-04-22 1988-04-22 Pharmazeutische matrix mit verzögerter freisetzung und verfahren
PCT/US1988/001377 WO1988008299A1 (en) 1987-04-22 1988-04-22 Pharmaceutical sustained release matrix and process

Publications (1)

Publication Number Publication Date
ATE86479T1 true ATE86479T1 (de) 1993-03-15

Family

ID=21915089

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88904333T ATE86479T1 (de) 1987-04-22 1988-04-22 Pharmazeutische matrix mit verzoegerter freisetzung und verfahren.

Country Status (21)

Country Link
US (1) US4806359A (de)
EP (2) EP0290168B1 (de)
JP (2) JP2519296B2 (de)
KR (1) KR960007750B1 (de)
AT (1) ATE86479T1 (de)
AU (2) AU604110B2 (de)
CA (1) CA1310272C (de)
DE (2) DE3865077D1 (de)
ES (1) ES2039277T3 (de)
GR (1) GR1000019B (de)
HK (1) HK22892A (de)
IE (1) IE62786B1 (de)
IN (1) IN165929B (de)
MY (1) MY103076A (de)
NO (1) NO176203C (de)
NZ (1) NZ224278A (de)
PH (1) PH25176A (de)
PT (1) PT87285B (de)
SG (1) SG104091G (de)
WO (1) WO1988008299A1 (de)
ZA (1) ZA882827B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
AU4664889A (en) * 1988-11-30 1990-06-26 Schering Corporation Sustained release diltiazem formulation
US4911921A (en) * 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
KR920002148A (ko) * 1990-07-03 1992-02-28 안드레아 엘. 콜비 비스테로이드계 소염제에 의해 유발된 위장 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
DE4140179C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Ibuprofen enthaltendes Arzneimittel
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140172C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DK138592D0 (da) * 1992-11-17 1992-11-17 Nycomed Dak As Tabletter
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
WO1995035099A1 (en) * 1994-06-20 1995-12-28 Kv Pharmaceutical Company Vitamin/nutrient dosage regimentation
WO1996012476A1 (en) * 1994-10-20 1996-05-02 Merck & Co., Inc. Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist
IT1276689B1 (it) * 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
JP3628809B2 (ja) * 1996-06-10 2005-03-16 アルケア株式会社 薬剤徐放性医療用配合物及びその製造方法
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US6110498A (en) * 1996-10-25 2000-08-29 Shire Laboratories, Inc. Osmotic drug delivery system
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
CN1208090C (zh) * 1999-03-31 2005-06-29 詹森药业有限公司 在控制释放制剂中的预胶凝淀粉
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
KR20030094244A (ko) * 2001-02-05 2003-12-11 알.피.쉐러 테크놀러지즈 인코포레이티드 약리학적 활성제의 맛을 감소시키기 위한 방법 및 조성물
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003077897A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
EP1648415A4 (de) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648407A4 (de) * 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1663169A4 (de) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
WO2005030181A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
AU2004275826A1 (en) * 2003-09-26 2005-04-07 Alza Corporation OROS push-stick for controlled delivery of active agents
CN1897924B (zh) 2003-09-26 2011-09-21 阿尔扎公司 能提供高载药量的药物包衣和提供它的方法
EP1765296A2 (de) * 2004-06-30 2007-03-28 Albemarle Corporation Granulat mit hohem ibuprofen-gehalt und seine herstellung und verwendung
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
DE102005037630A1 (de) 2005-08-09 2007-02-15 Glatt Gmbh Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
ZA200806138B (en) * 2005-12-16 2009-11-25 Hanmi Pharm Ind Co Ltd Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
WO2008128140A1 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Delivery device and method for forming the same
US9629806B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
WO2010014952A2 (en) * 2008-07-31 2010-02-04 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
EP2968652B1 (de) 2013-03-13 2020-07-22 Avery Dennison Corporation Verbesserung von hafteigenschaften
CN110037994B (zh) * 2019-05-24 2022-04-12 中国药科大学 一种布洛芬速释缓释双层片及其制备方法
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773921A (en) * 1971-11-15 1973-11-20 Hoffmann La Roche Therapeutic compositions
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4308251A (en) * 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
FR2532177A1 (fr) * 1982-08-30 1984-03-02 Being Well Products Inc Complement nutritionnel a zones de liberation determinees et son procede de fabrication
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
CA1261260A (en) * 1984-04-16 1989-09-26 Anil Salpekar Directly compressible codeine salt compositions
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets

Also Published As

Publication number Publication date
SG104091G (en) 1992-02-14
MY103076A (en) 1993-04-30
IE62786B1 (en) 1995-02-22
WO1988008299A1 (en) 1988-11-03
DE3879080T2 (de) 1993-07-15
NO881732D0 (no) 1988-04-21
AU1719788A (en) 1988-12-02
CA1310272C (en) 1992-11-17
EP0312581A1 (de) 1989-04-26
IN165929B (de) 1990-02-10
KR960007750B1 (ko) 1996-06-12
EP0290168A1 (de) 1988-11-09
JP2776856B2 (ja) 1998-07-16
AU604110B2 (en) 1990-12-06
JPS63280021A (ja) 1988-11-17
PT87285A (pt) 1988-05-01
ZA882827B (en) 1989-12-27
AU603675B2 (en) 1990-11-22
NO881732L (no) 1988-10-24
EP0290168B1 (de) 1991-09-25
HK22892A (en) 1992-04-03
NO176203C (no) 1995-02-22
US4806359A (en) 1989-02-21
KR880012213A (ko) 1988-11-26
JP2519296B2 (ja) 1996-07-31
GR1000019B (el) 1990-01-31
DE3879080D1 (de) 1993-04-15
IE881195L (en) 1988-10-22
EP0312581B1 (de) 1993-03-10
ES2039277T3 (es) 1993-09-16
NZ224278A (en) 1990-09-26
GR880100258A (en) 1989-01-31
PT87285B (pt) 1992-08-31
PH25176A (en) 1991-03-27
AU1477488A (en) 1988-10-27
JPH01503070A (ja) 1989-10-19
NO176203B (no) 1994-11-14
DE3865077D1 (de) 1991-10-31

Similar Documents

Publication Publication Date Title
ATE86479T1 (de) Pharmazeutische matrix mit verzoegerter freisetzung und verfahren.
GR1000254B (el) Μεθοδος παρασκευης διαμορφωσεως ακεταμινοφαινης βραδειας απελευθερωσεως απο το στομα.
KR880010757A (ko) 제약정제, 제약과립 및 그의 제조방법
DE69006365D1 (de) Unbeschichtete pharmazeutische reaktionstablette.
NZ234587A (en) A chewable pharmaceutical tablet of compressed coated granules
ES2055177T3 (es) Composicion de gemfibrozil con liberacion modificada.
ATE82680T1 (de) Kautablette.
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
DE69020541D1 (de) Granulate mit hohem ibuprofengehalt.
GB1296505A (de)
SE8701479L (sv) Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
ATE185266T1 (de) Schnell auflösende orale darreichungsform
ATE92752T1 (de) Spruehgetrocknete ibuprofen-zusammensetzungen.
ATE86489T1 (de) Hilfsmittelfreie riboflavingranulate.
FR2106566A1 (en) Tabletting active materials - by compressing encapsulated particles
JPS54126722A (en) Slow release antibiotic tablet
TH6682A (th) สูตรผสมแอเซทามิโนเฟนชนิดปลดปล่อยเป็นเวลานานสำหรับใช้ทางปากและกรรมวิธีในการผลิต

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time